Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients

Catheterization and Cardiovascular Interventions

Volumn 78, Issue 7, 2011, Pages 1078-1085

  Otsuka, Yoritaka ^a,b   Saito, Shigeru ^c   Nakamura, Masato ^d   Shuto, Hideo ^e   Mitsudo, Kazuaki ^f  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b FUKUOKA WAJIRO HOSPITAL   (Japan)

^c SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^d TOHO UNIVERSITY   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

drug eluting stent; percutaneous coronary intervention; pharmacokinetics

Indexed keywords

EVEROLIMUS; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG RELEASE; FEMALE; HUMAN; JAPANESE; MALE; MATERIAL COATING; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY (TOPIC); OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; STABLE ANGINA PECTORIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSTABLE ANGINA PECTORIS;

AGED; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; FEMALE; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 81855164802     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23096     Document Type: Article

References (33)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
2. Marx SO, Jayaraman T, Go LO, Marks AR,. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-417.
3. Windecker S, Roffi M, Meier B,. Sirolimus eluting stent: A new era in interventional cardiology? Curr Pharm Des 2003; 9: 1077-1094. (Pubitemid 36443208)
4. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ,. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193. (Pubitemid 32830406)
5. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL,. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-188. (Pubitemid 34747967)
6. Otsuka Y, Nakamura M, Yasuda S, Kozuma K, Hara H, Morii I, Kawamura A, Sase K, Miyazaki S,. Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients. J Cardiovasc Pharmacol 2005; 46: 468-473. (Pubitemid 41407575)
7. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342. (Pubitemid 352001347)
8. Nakazawa G, Finn AV, Kolodgie FD, Virmani R,. A review of current devices and a look at new technology: Drug-eluting stents. Expert Rev Med Devices 2009; 6: 33-42.
9. Kandzari DE, Leon MB,. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006; 19: 405-413. (Pubitemid 44511071)
10. Hwang CW, Wu D, Edelman ER,. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001; 104: 600-605. (Pubitemid 32738132)
11. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D,. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv 2009; 2: 1169-1177.
12. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE,. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112: 2833-2839. (Pubitemid 41641678)
13. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P,. The next-generation endeavor resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 2007; 3: 50-53.
14. Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E,. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006; 98: 443-446. (Pubitemid 44177576)
15. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D,. Randomized comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. EuroIntervention 2007; 2: 426-434.
16. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. (Pubitemid 43929240)
17. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
18. Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, Jüni P, di Mario C,. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: A LEADERS trial sub-study. Eur Heart J 2010; 31: 165-176.
19. Schächinger V, Britten MB, Zeiher AM,. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906. (Pubitemid 30225269)
20. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ,. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent. JACC Cardiovasc Interv 2008; 1: 65-71. (Pubitemid 351445416)
21. Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, Kim EJ, Rha SW, Park CG, Oh DJ,. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009; 53: 1653-1659.
22. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, Barbato E, Beleslin B, Sagic D, De Bruyne B, Bartunek J, Wijns W,. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: Evidence for device-specific responses. Circ Cardiovasc Interv 2008; 1: 193-200.
23. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, Nedeljkovic M, Orlic D, Milosavljevic B, Topic D, Karanovic N, Wijns W,; NOBORI CORE Investigators. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129. (Pubitemid 351721001)
24. Fukuda D, Sata M, Tanaka K, Nagai R,. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111: 926-931. (Pubitemid 40279896)
25. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K,. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: Impact on restenosis. Circulation 2007; 115: 553-561. (Pubitemid 46226164)
26. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J,. Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 2005; 524: 19-29. (Pubitemid 41606808)
27. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC,. Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 2005; 112: 2002-2011. (Pubitemid 41377420)
28. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ,. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697. (Pubitemid 26320276)
29. Shiroto T, Yasuda S, Tsuburaya R, Ito Y, Takahashi J, Ito K, Ishibashi-Ueda H, Shimokawa H,. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo. J Am Coll Cardiol 2009; 54: 2321-2329.
30. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB III, Robinson KA, Chronos NA, Hou D,. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv 2009; 2: 253-262.
31. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, Tai JT, Abraham GM, Pacetti SD, Chan YF, Nakazawa G, Kolodgie FD, Virmani R, Ding NN, Coleman LA,. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials 2010; 31: 648-657.
32. Bottiger Y, Sawe J, Brattstrom C, Tollemar J, Burke JT, Häss G, Zimmerman JJ,. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001; 69: 32-40. (Pubitemid 32108669)
33. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C,. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002; 42: 222-228. (Pubitemid 34101356)